Novo Protects Its Own – Sues Four Companies

By: Miranda Schwartz

Novo Nordisk has recently filed a patent infringement lawsuit in New Jersey Federal Court against Genentech, Eli Lilly, Pharmacia & Upjohn and Serono corporations. The companies all make and/or sell biosynthetic human growth hormone products that compete with Novo’s Norditropin.

This is not the first time Novo has had patent problems. Norditropin was approved by the FDA in May 1995, but due to patent litigation between Novo and Genentech, it was not launched until February 1997.

Novo says its patent is infringed on by Genentech’s Nutropin and Nutropin AQ, Lilly’s Humatrope, P&U’s Genotropin and Serono’s Serostim and Saizen products. Lilly is also accused of two additional patent infringements.



Diabetes Health Medical Disclaimer
The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. All content, including text, graphics, images, and information, contained on or available through this website is for general information purposes only. Opinions expressed here are the opinions of writers, contributors, and commentators, and are not necessarily those of Diabetes Health. Never disregard professional medical advice or delay seeking medical treatment because of something you have read on or accessed through this website.